About Allergy Therapeutics
Allergy Therapeutics is a company based in Worthing (United Kingdom) founded in 1998.. The company has 612 employees as of June 30, 2024. Allergy Therapeutics offers products and services including Allergy Treatments, Research Services, and Adjuvant Systems. Allergy Therapeutics operates in a competitive market with competitors including Altimmune, Biological E, Stallergenes Greer, IgGenix and Vaxart, among others.
- Headquarter Worthing, United Kingdom
- Employees 612 as on 30 Jun, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Allergy Therapeutics Plc
-
Annual Revenue
$69.82 M (USD)-7.36as on Jun 30, 2024
-
Net Profit
$-50.87 M (USD)6.63as on Jun 30, 2024
-
EBITDA
$-39.74 M (USD)-2.6as on Jun 30, 2024
-
Latest Funding Round
$13.85 M (USD), Post-IPO
Jul 19, 2018
-
Investors
-
Employee Count
612
as on Jun 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Allergy Therapeutics
Allergy Therapeutics is a publicly listed company on the LSE with ticker symbol AGY in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Allergy Therapeutics
Allergy Therapeutics offers a comprehensive portfolio of products and services, including Allergy Treatments, Research Services, and Adjuvant Systems. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops convenient therapies for allergy and immune disorders
Provides expertise in allergy treatment innovation
Offers systems for enhancing immune responses
Unlock access to complete
Unlock access to complete
Funding Insights of Allergy Therapeutics
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $13.9M
-
First Round
First Round
(01 Jun 2009)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2018 | Amount | Post-IPO - Allergy Therapeutics | Valuation |
investors |
|
| Nov, 2015 | Amount | Post-IPO - Allergy Therapeutics | Valuation |
investors |
|
| Mar, 2015 | Amount | Post-IPO - Allergy Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Allergy Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Allergy Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Allergy Therapeutics Comparisons
Competitors of Allergy Therapeutics
Allergy Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Altimmune, Biological E, Stallergenes Greer, IgGenix and Vaxart, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Allergen immunotherapies for respiratory allergies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for treating multiple infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Allergy Therapeutics
Frequently Asked Questions about Allergy Therapeutics
When was Allergy Therapeutics founded?
Allergy Therapeutics was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Where is Allergy Therapeutics located?
Allergy Therapeutics is headquartered in Worthing, United Kingdom.
How many employees does Allergy Therapeutics have?
As of Jun 30, 2024, the latest employee count at Allergy Therapeutics is 612.
What is the annual revenue of Allergy Therapeutics?
Annual revenue of Allergy Therapeutics is $69.82M as on Jun 30, 2024.
What does Allergy Therapeutics do?
Founded in 1998 and based in Worthing, United Kingdom, operations in the biopharmaceutical sector are centered on research and development of allergy treatments. Subcutaneous immunotherapy and modified allergen tyrosin-absorbed therapies are focused on for diagnosing and treating allergy-related conditions. Aluminum-free vaccines and diagnostic tools are produced to address these health issues.
Who are the top competitors of Allergy Therapeutics?
Allergy Therapeutics's top competitors include Biological E, Stallergenes Greer and IgGenix.
What products or services does Allergy Therapeutics offer?
Allergy Therapeutics offers Allergy Treatments, Research Services, and Adjuvant Systems.
Is Allergy Therapeutics publicly traded?
Yes, Allergy Therapeutics is publicly traded on LSE under the ticker symbol AGY.
What is Allergy Therapeutics's ticker symbol?
The ticker symbol of Allergy Therapeutics is AGY on LSE.